Description: Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
Home Page: www.quantum-genomics.com
33 rue Marbeuf
Paris,
75008
France
Phone:
33 1 85 34 77 70
Officers
| Name | Title |
|---|---|
| Dr. Jean-Philippe Milon | CEO, MD & Director |
| Mr. Benoît Gueugnon | Admin. & Financial Director, VP of Fin. and CFO |
| Mr. Stephane Cohen | Chief Operating Officer |
| Dr. Bruno Besse | Chief Medical Officer |
| Dr. Sarah Merlen-Boulenger | Head of Regulatory Affairs |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0.1778 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3167 |
| Price-to-Sales TTM: | 1.0718 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |